Key clinical point: In a cohort of FL patients aged 80 years or older, FL-directed therapy was associated with an overall survival benefit.
Major finding: Median overall survival for the treated group was 4.31 years vs. 2.86 years for the untreated group.
Study details: A retrospective database cohort study of 3,705 patients aged 80+ years, diagnosed with FL between 2000 and 2013.
Disclosures: Financial support for this study was provided by independent research funding from Bayer. One of the authors is employed by Bayer.
Albarmawi H et al. J Geriatric Oncol. 2020;11:55-61.